Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma
- 18 March 2003
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (S1) , S65-S81
- https://doi.org/10.1007/s00259-003-1164-7
Abstract
Until recently, gallium-67 scintigraphy (GS) has been the best available functional imaging modality for evaluating patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). The diagnostic accuracy of GS in detecting lymphoma is based on optimisation of the imaging protocol, knowledge of potential physiological and benign sites of 67Ga uptake, and the Ga avidity characteristics of the individual lymphoma. As 67Ga is a tumour viability agent, the role of GS is primarily at follow-up. A residual mass persisting on CT after treatment poses a common clinical dilemma: it may indicate the presence of viable lymphoma, which requires further treatment, or it can be benign, consisting of only fibrotic and necrotic tissues. GS can successfully differentiate between these conditions. Routine follow-up with GS may allow early diagnosis of recurrence and early institution of treatment. Reversion of a positive GS to a negative test, and the rapidity with which this occurs has a high predictive value for the outcome of the individual patient. Lymphoma showing a normal GS early during treatment has a better prognosis than lymphoma with persistence of pathological findings. Other tumour-seeking single-photon emitting agents, such as thallium-201, technetium-99m methoxyisobutylisonitrile and indium-111 octreotide, have been investigated in lymphoma, primarily as an alternative to GS in specific clinical settings, but are of limited value. The role of radioimmunoscintigraphy is gaining importance in conjunction with radioimmunotherapy. Fluorine-18 fluorodeoxyglucose (FDG) imaging of lymphoma using either dedicated or camera-based PET systems is gradually replacing GS for assessment of lymphoma. FDG overcomes some of the limitations of GS while sharing its tumour viability characteristics. The extensive clinical knowledge and experience accumulated over three decades with GS in lymphoma provides a solid background as well as a model for the assessment of new functional imaging techniques.Keywords
This publication has 152 references indexed in Scilit:
- 25. Positron Emission Tomography in Hodgkin's Disease Correlation with Computed Tomography and Gallium 67 Citrate ImagingClinical Positron Imaging, 2000
- Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's diseaseAnnals of Oncology, 1997
- Somatostatin receptor scintigraphy in the initial staging of Hodgkin's diseaseBritish Journal of Haematology, 1996
- GA-67-CITRATE VERSUS TC-99M-LABELLED LL2-FAB'-FRAGMENTS (ANTI-CD22) IN THE STAGING OF B-CELL NON-HODGKINʼS LYMPHOMA (NHL)Journal of Immunotherapy, 1994
- Clinical applications of fusion imaging in oncologyNuclear Medicine and Biology, 1994
- Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkinʼs lymphoma?Nuclear Medicine Communications, 1992
- Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- A comparison of gallium-67 single photon emission computed tomography and computed tomography in mediastinal Hodgkin's diseaseEuropean Journal Of Cancer, 1992
- CD71 phenotype and the value of gallium imaging in lymphomasAmerican Journal of Hematology, 1991
- Current role of gallium scanning in the management of lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1990